About Us

Procaps Group, S.A. (“Procaps”)  is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and nearly 5,000 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products, prescription pharmaceutical drugs (Rx), nutritional supplements, and high-potency clinical solutions.

20-F

This Annual Report contains the annual audited consolidated financial statements of Procaps Group, S.A. as of December 31, 2023, 2022 restated and January 1, 2022 restated, and for the years ended December 31, 2023, 2022 restated and 2021 restated (the “Annual Audited Consolidated Financial Statements”).

View More

Recent News

Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership

April 9, 2025

New Investors Take Over the Strategic Leadership as Headquarters Move to Bogotá, Marking the Start of a New Chapter of Growth, Execution, and Transformation under Enhanced Governance Company Accelerates Turnaround with Leadership Changes, Regional Realignment, Sale of Non-Core Assets and Renewed

View More

Pharmaceutical Group dedicated to delivering health and nutrition

Pharmaceutical Group
dedicated to delivering
health and nutrition

We employ over 5.000 people across 13 countries

We employ over 5.000 people across 13 countries
 

Our products reach 50+ markets

Our products reach 
50+ markets